Xcel Research

• Provider Profile Name: Xcel Research (operating as Xcel Research LLC / xcelpeptides.com)
• Website: xcelresearch.com / xcelpeptides.com
• Contact: Andrew Pierce | Support@XcelPeptides.com
• Registered Address: 1309 Coffeen Ave., Suite 12238, Sheridan, WY 82801 

Approach

Xcel Research appears in the weightlossinjections.com directory as a virtual GLP-1 telehealth provider serving Florida with compounded semaglutide and tirzepatide listed as possible offerings. Research of the company’s actual operations and FDA public records reveals a fundamentally different picture. Xcel Research is an online retailer selling peptide products labeled “for research use only” and it received a formal FDA Warning Letter in December 2024 for violations of federal drug law. Like Veronvy, reviewed elsewhere in this series, the directory’s classification of this entity as a telehealth provider is a material inaccuracy.

About the Company

“Xcel Research Consulting, Inc.” is a separate public health consulting organization unrelated to the company being reviewed here. The relevant entity is Xcel Research LLC, operating xcelpeptides.com, which shares its name but is an entirely different operation, a research peptide retailer that sells peptide products online.

FDA Warning Letter — December 10, 2024

The FDA reviewed xcelpeptides.com in October 2024 and issued a Warning Letter to Xcel Research LLC, addressed to Andrew Pierce at 1309 Coffeen Ave., Suite 12238, Sheridan, WY, on December 10, 2024. The letter found that the website offered products including “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN” for sale in the United States, classifying them as unapproved new drugs introduced into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.

The FDA investigated the websites and social media pages of Xcel Research and found evidence that the company was positioning its products “to prevent, treat, or cure disease conditions and/or affect the structure or function of the body” despite marketing them as being for research purposes only. Such claims are in violation of the FD&C Act, which prohibits the sale of unapproved drugs.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Xcel Research was one of four companies to receive warning letters in December 2024, alongside Prime Peptides, Summit Research Peptides, and Swisschems. The companies were given 15 working days to take corrective steps and explain preventative actions being taken to mitigate future violations.

This Warning Letter is more serious in one respect than the misbranding violations flagged for Belle Health and Body Good Studio: those platforms were legitimate telehealth providers that used inaccurate marketing language about their compounded medications. Xcel Research is a research peptide vendor that was selling unapproved drug substances including experimental compounds like retatrutide and mazdutide that have no FDA approval and no established human safety profile directly to the public through a “research use only” label the FDA found to be a legal fiction.

GLP-1 Offerings and Weight Loss Services

Xcel Research does not offer a GLP-1 telehealth program. It does not conduct clinical consultations, evaluate patients, or prescribe medications. The products it sold under product names like “SEMA” and “CagriLean” were research peptide products, chemical compounds sold without prescriptions, without licensed prescribers, and without any clinical oversight.

The directory’s pricing data reflects this reality directly. The user-reported prices of $79–$149 for “GLP-1 (SM)” and $109 for “GLP-2 (TZ)” with notes describing them as “for research use” are not telehealth program prices. They are retail prices for research peptide vials, the same category of product the FDA’s Warning Letter specifically targeted.

What Xcel Research does not provide:

• No prescribing of any kind
• No licensed clinical staff
• No pharmacy partnerships under any licensed compounding framework
• No patient safety evaluation, dose titration guidance, or follow-up care
• No HIPAA-compliant clinical infrastructure

Pricing by Type — and What Reviewers Say

The directory’s reported pricing of $79–$149 for semaglutide products and $109 for tirzepatide, explicitly labeled “for research use,” reflects the research peptide retail market not a clinical weight loss program. These prices are substantially lower than any legitimate GLP-1 telehealth program reviewed in this series, which is consistent with the nature of unregulated, prescription-free research peptide sales.

No independent patient reviews exist for Xcel Research as a weight loss program because it has not operated as one. No Trustpilot profile, no Google Business listing, and no consumer review pool was found. The directory itself lists zero approved reviews.

Reviews from Trustpilot and Google

No Trustpilot profile or Google Business listing was found for Xcel Research. No independent patient review pool exists through any major third-party platform. Given the nature of the company’s actual operations, a research peptide vendor, not a clinical provider, the absence of health-outcome reviews is expected.

Compounding Pharmacies Used

Xcel Research does not work with compounding pharmacies and does not operate within a licensed pharmaceutical compounding framework.

The products it sold were offered directly through its website to consumers without prescriptions, licensed prescribers, or pharmacy dispensing oversight, the structural opposite of a legitimate 503A or 503B compounding arrangement.

Note: Xcel Research LLC is a research peptide retailer that received an FDA Warning Letter on December 10, 2024, for selling unapproved drug substances including semaglutide, retatrutide, cagrilintide, mazdutide, and survodutide, in violation of the Federal Food, Drug, and Cosmetic Act. Note also that “Xcel Research Consulting, Inc,” a public health consulting firm, is a separate entity with no connection to Xcel Research LLC or xcelpeptides.com.